Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03490929 · ClinicalTrials.gov registry record · Phase 4
CEUS for Blunt Abdominal Trauma in Children
A Phase 4 study of Trauma Abdomen, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 146
- Enrollment target
- 2
- Study locations
NCT03490929: Recruiting Phase 4 study of Trauma Abdomen, sponsored by Children's Hospital of Philadelphia.
NCT03490929 is a Phase 4 study of Trauma Abdomen that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 146 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03490929, a Phase 4 study of Trauma Abdomen, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 146 participants
- Enrollment target
- 2
- Study locations
Study Summary
Children with blunt abdominal trauma often get a CT as the first line imaging to evaluate for intra-abdominal organ injury. CT scans have some downsides with regard to radiation exposure, costs, and need for transport. Contrast enhanced ultrasonography has recently shown some promise as a way to detect intra-abdominal organ injury and may be able to replace the need for conventional CT scanning, without the need for ionizing radiation and the ability to be performed at the bedside.
Primary Outcome
calculation of sensitivity of CEUS for organ injury, as compared to gold standard CT
Conditions Studied
Interventions
- DRUG Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
- DEVICE contrast-enhanced ultrasound
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT03490929 shows while recruiting
NCT03490929 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Trauma Abdomen appearing as the primary indexed condition, and to 2 interventions - of which Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON] is the first listed.
NCT03490929 reports a single indexed study location in Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03490929 about?
NCT03490929 is a clinical study titled "CEUS for Blunt Abdominal Trauma in Children". Children with blunt abdominal trauma often get a CT as the first line imaging to evaluate for intra-abdominal organ injury. CT scans have some downsides with regard to radiation exposure, costs, and need for transport. Contrast enhanced ultrasonography has recently shown some promise as a way to det...
What is the current status of trial NCT03490929?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 146 participants. The study started on 2018-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03490929 study?
This clinical trial studies the following conditions: Trauma Abdomen.
What interventions are being tested in trial NCT03490929?
The interventions under investigation include: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON] (DRUG), contrast-enhanced ultrasound (DEVICE).
Who is sponsoring clinical trial NCT03490929?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03490929 being conducted?
This trial has 2 study locations across Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03490929's enrollment target sits among peer trials
146 571st of 2000 higher than 1,429 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
- NCT05398276 · 146 participants · Phase 2
Behavioral Exposure for Introceptive Tolerance RCT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI